CellWell record HH-329117
Molecular remission after tyrosine kinase inhibitor cessation in chronic myeloid leukemia (CML): A systematic review and meta-analysis.
Songphol Tungjitviboonkun; Brian Schult; C. Seaman
Journal of Clinical Oncology ยท 2026
In plain language
Approximately 52% of chronic-phase CML patients sustained treatment-free remission at 36 months after discontinuing tyrosine kinase inhibitor therapy.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-329117
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.